Who
Jack L. Wyszomierski
Director
Company insider
Files Form 4 as: Director, XOMA Royalty; Director, Exelixis; Director, SiteOne Landscape Supply; Director, Athersys, Inc / New; Director, Unigene Laboratories.
In numbers
- Trades disclosed
- 184
- Buys
- 1
- Sells
- 14
- Bought
- $105K
- Sold
- $12.3M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 2 May 2006
- Last trade
- 14 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Jul 2026filed 14 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code J | —21,828 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,000 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,366 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —8,000 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —2,366 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —5,052 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —8,167 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —6,152 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —5,101 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —8,996 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —10,967 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,052 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,167 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —6,152 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,101 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,996 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,967 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royalty | SEC FORM 4 Code J | —21,828 | filing |
| 1 Jun 2026filed 3 Jun 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $198K3,925 at $50.55 | filing |
| 1 Jun 2026filed 3 Jun 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $198K3,925 at $50.55 | filing |
News
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026Exelixis v. MSN Shows the Reach of Earlier Genus PatentsEXEL · natlawreview.com · 7 Oct 2026
0 headlines in the last 90 days name Jack L. Wyszomierski; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.